Eagle Asset Management Inc Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Eagle Asset Management Inc reduced its stake in Pfizer by 2.99% during the most recent quarter end. The investment management company now holds a total of 3,979,412 shares of Pfizer which is valued at $131,837,920 after selling 122,558 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Pfizer makes up approximately 0.91% of Eagle Asset Management Inc’s portfolio.

Other Hedge Funds, Including , Nadler Financial Group reduced its stake in PFE by selling 236 shares or 0.8% in the most recent quarter. The Hedge Fund company now holds 29,316 shares of PFE which is valued at $983,845. Pfizer makes up approx 0.39% of Nadler Financial Group’s portfolio.Pure Financial Advisors boosted its stake in PFE in the latest quarter, The investment management firm added 4,228 additional shares and now holds a total of 21,799 shares of Pfizer which is valued at $731,574. Pfizer makes up approx 0.24% of Pure Financial Advisors’s portfolio.Exxonmobil Investment Management Inc Tx reduced its stake in PFE by selling 21,110 shares or 1.34% in the most recent quarter. The Hedge Fund company now holds 1,548,778 shares of PFE which is valued at $51,976,990. Pfizer makes up approx 1.09% of Exxonmobil Investment Management Inc Tx’s portfolio.Independent Portfolio Consultants reduced its stake in PFE by selling 120 shares or 0.51% in the most recent quarter. The Hedge Fund company now holds 23,378 shares of PFE which is valued at $792,514. Pfizer makes up approx 0.25% of Independent Portfolio Consultants’s portfolio.

Pfizer closed down -0.48 points or -1.43% at $33.13 with 1,73,32,125 shares getting traded on Tuesday. Post opening the session at $33.56, the shares hit an intraday low of $32.94 and an intraday high of $33.57 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Investors should note that on Sep 22, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Nov 9, 2016 as the ex-dividend date and fixed the record date on Nov 11, 2016. The payable date has been fixed on Dec 1, 2016.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.